{"success":true,"data":{"pressRelease":{"id":"114207","rtpr_id":"nGNE62374h","ticker":"NOVOB","exchange":"Nasdaq Copenhagen","all_tickers":["NOVOB"],"title":"REG-Novo Nordisk A/S - share repurchase programme","author":"Globe Newswire","published_at":"2026-08-10T13:35:33.064Z","article_body":"Bagsværd, Denmark, 10 August 2026 – On 6 May 2026, Novo Nordisk initiated\na share repurchase programme in accordance with Article 5 of Regulation No\n596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the\nCommission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the \"Safe\nHarbour Rules\"). This programme is part of the overall share repurchase\nprogramme of up to DKK 15 billion to be executed during a 12-month period\nbeginning 4 February 2026.\n\nUnder the programme initiated 6 May 2026, Novo Nordisk will repurchase B\nshares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026\nto 1 February 2027.\n\nSince the announcement 4 August 2026, the following transactions have been\nmade:\n\n Number of B shares Average purchase price Transaction value, DKK \n Accumulated, last announcement 12,305,000 3,733,256,468 \n 4 August 2026 200,000 308.29 61,657,106 \n 5 August 2026 215,000 294.26 63,266,938 \n 6 August 2026 205,000 296.54 60,790,017 \n 7 August 2026 200,000 305.49 61,097,391 \n Accumulated under the programme 13,125,000 3,980,067,920 \n\nThe details for each transaction made under the share repurchase programme are\npublished on novonordisk.com\n(https://www.globenewswire.com/Tracker?data=plvPtLYWCfEtl-0Cp9A1jgtTGJtdacwwO2X2cFsD4jPGsJPpaDonGqM8M0UztV80GJeoLMVqdEljDM6X_CAFdxqftR9HIy_M5UpEq_7HzVMe6GqbwIO35jVui48mZ_-KoLa-lSRNAGHhImlrI1DmvamOzDJk0gYFtcfEr1affv4=).\n\n\nTransactions related to Novo Nordisk’s incentive programmes have resulted in\na net transfer from Novo Nordisk of 3,144,604 shared in the period from 4\nAugust 2026 to 7 August 2026. The shares in these transactions were not part\nof the Safe Harbour repurchase programme.\nWith the transactions stated above, Novo Nordisk owns a total of 41,924,876 B\nshares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share\ncapital. The total amount of A and B shares in the company is 4,465,000,000\nincluding treasury shares.\n\nNovo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion\nduring a 12-month period beginning 4 February 2026. As of 7 August 2026, Novo\nNordisk has since 4 February 2026 repurchased a total 27,884,179 B shares at\nan average share price of DKK 279.01 per B share equal to a transaction value\nof DKK 7,780,067,909.\n\nNovo Nordisk is a leading global healthcare company founded in 1923 and\nheadquartered in Denmark. Our purpose is to drive change to defeat serious\nchronic diseases built upon our heritage in diabetes. We do so by pioneering\nscientific breakthroughs, expanding access to our medicines and working to\nprevent and ultimately cure disease. Novo Nordisk employs about 68,800 people\nin 80 countries and markets its products in around 170 countries. Novo\nNordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are\nlisted on the New York Stock Exchange (NVO). For more information, visit\nnovonordisk.com,\n(https://www.globenewswire.com/Tracker?data=plvPtLYWCfEtl-0Cp9A1jm3mbcV73cjGm-7shORtYFGmheZKwBdNZiA5Ycgs3bPNmdM-PJKSAfjXxrvB1Y8s97dD5yW_FxLeSHgZXiTO4wc=)\nFacebook\n(https://www.globenewswire.com/Tracker?data=a8ezbcZGwzal4WU8xP4RZN6GZhHBjJzljjqjcNH9ocMOXMT3q7ovq-UraEQ3g1-f88GUvb4QoSYj50a79Qomtr5C3G5JFUxqC1DrDgPXm84=),\nInstagram\n(https://www.globenewswire.com/Tracker?data=VBRvxhdXJ0tZZxBP3kMk89LGGswkGLxRanBPqzs9odaXJhgdcQQTZ-tRAYyHniUK_wFerCochn3OVEwEBe6trCApDvtI1coKHsGPDonq-2I=),\nX\n(https://www.globenewswire.com/Tracker?data=w38wxo3sjZ9hcUDbIX4jDYBTePj4-BervZIMGVuVplH6KDRjqhk7Sqh_8FAx75YeaV9aNCQMQrJd9Rv5k1NQzA==),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=rVVgojXzDHERoDL3Nt-JGcDs6jTBSMW-nLoHQZnPSTYDM0j4XRuG9W0nozQI0HfpYrNbKMifJ6M0QQu8TSpj7t1g3_wYnMCEPh22XiTnydytUNUnPUNZKRoyUgE9ubtH)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=TayXhLCbpk48B-hjwvNfogwRFCvRCa3n33UwyQKHB1MDmojNkH_A0GFXxCANzDk6G9dq6SaEz2g6MT83WIA5qJ9KeTxDmh561wqQqAk2jGU=).\n\nContacts for further information\n\n Media: \n Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com \n Investors: \n Michael Novod +45 3075 6050 nvno@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com \n Alex Bruce +45 3444 2613 axeu@novonordisk.com Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com \n Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com \n Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com \n\nCompany announcement No 50 / 2026\n\nAttachments\n* CA260810_Safe Harbour\n(https://ml-eu.globenewswire.com/Resource/Download/b8280260-28bb-455d-93ee-ec4c58ba82b1)\n \n* 260810_Safe harbour transaction details\n(https://ml-eu.globenewswire.com/Resource/Download/0fc3d292-a907-42d5-b4bb-cab53619c384)","article_body_html":"","raw_payload":{"data":{"id":"nGNE62374h","title":"REG-Novo Nordisk A/S - share repurchase programme","author":"Globe Newswire","ticker":"NOVOB","created":"2026-08-10T13:35:33.064Z","tickers":["NOVOB"],"exchange":"Nasdaq Copenhagen","article_body":"Bagsværd, Denmark, 10 August 2026 – On 6 May 2026, Novo Nordisk initiated\na share repurchase programme in accordance with Article 5 of Regulation No\n596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the\nCommission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the \"Safe\nHarbour Rules\"). This programme is part of the overall share repurchase\nprogramme of up to DKK 15 billion to be executed during a 12-month period\nbeginning 4 February 2026.\n\nUnder the programme initiated 6 May 2026, Novo Nordisk will repurchase B\nshares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026\nto 1 February 2027.\n\nSince the announcement 4 August 2026, the following transactions have been\nmade:\n\n Number of B shares Average purchase price Transaction value, DKK \n Accumulated, last announcement 12,305,000 3,733,256,468 \n 4 August 2026 200,000 308.29 61,657,106 \n 5 August 2026 215,000 294.26 63,266,938 \n 6 August 2026 205,000 296.54 60,790,017 \n 7 August 2026 200,000 305.49 61,097,391 \n Accumulated under the programme 13,125,000 3,980,067,920 \n\nThe details for each transaction made under the share repurchase programme are\npublished on novonordisk.com\n(https://www.globenewswire.com/Tracker?data=plvPtLYWCfEtl-0Cp9A1jgtTGJtdacwwO2X2cFsD4jPGsJPpaDonGqM8M0UztV80GJeoLMVqdEljDM6X_CAFdxqftR9HIy_M5UpEq_7HzVMe6GqbwIO35jVui48mZ_-KoLa-lSRNAGHhImlrI1DmvamOzDJk0gYFtcfEr1affv4=).\n\n\nTransactions related to Novo Nordisk’s incentive programmes have resulted in\na net transfer from Novo Nordisk of 3,144,604 shared in the period from 4\nAugust 2026 to 7 August 2026. The shares in these transactions were not part\nof the Safe Harbour repurchase programme.\nWith the transactions stated above, Novo Nordisk owns a total of 41,924,876 B\nshares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share\ncapital. The total amount of A and B shares in the company is 4,465,000,000\nincluding treasury shares.\n\nNovo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion\nduring a 12-month period beginning 4 February 2026. As of 7 August 2026, Novo\nNordisk has since 4 February 2026 repurchased a total 27,884,179 B shares at\nan average share price of DKK 279.01 per B share equal to a transaction value\nof DKK 7,780,067,909.\n\nNovo Nordisk is a leading global healthcare company founded in 1923 and\nheadquartered in Denmark. Our purpose is to drive change to defeat serious\nchronic diseases built upon our heritage in diabetes. We do so by pioneering\nscientific breakthroughs, expanding access to our medicines and working to\nprevent and ultimately cure disease. Novo Nordisk employs about 68,800 people\nin 80 countries and markets its products in around 170 countries. Novo\nNordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are\nlisted on the New York Stock Exchange (NVO). For more information, visit\nnovonordisk.com,\n(https://www.globenewswire.com/Tracker?data=plvPtLYWCfEtl-0Cp9A1jm3mbcV73cjGm-7shORtYFGmheZKwBdNZiA5Ycgs3bPNmdM-PJKSAfjXxrvB1Y8s97dD5yW_FxLeSHgZXiTO4wc=)\nFacebook\n(https://www.globenewswire.com/Tracker?data=a8ezbcZGwzal4WU8xP4RZN6GZhHBjJzljjqjcNH9ocMOXMT3q7ovq-UraEQ3g1-f88GUvb4QoSYj50a79Qomtr5C3G5JFUxqC1DrDgPXm84=),\nInstagram\n(https://www.globenewswire.com/Tracker?data=VBRvxhdXJ0tZZxBP3kMk89LGGswkGLxRanBPqzs9odaXJhgdcQQTZ-tRAYyHniUK_wFerCochn3OVEwEBe6trCApDvtI1coKHsGPDonq-2I=),\nX\n(https://www.globenewswire.com/Tracker?data=w38wxo3sjZ9hcUDbIX4jDYBTePj4-BervZIMGVuVplH6KDRjqhk7Sqh_8FAx75YeaV9aNCQMQrJd9Rv5k1NQzA==),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=rVVgojXzDHERoDL3Nt-JGcDs6jTBSMW-nLoHQZnPSTYDM0j4XRuG9W0nozQI0HfpYrNbKMifJ6M0QQu8TSpj7t1g3_wYnMCEPh22XiTnydytUNUnPUNZKRoyUgE9ubtH)\nand YouTube\n(https://www.globenewswire.com/Tracker?data=TayXhLCbpk48B-hjwvNfogwRFCvRCa3n33UwyQKHB1MDmojNkH_A0GFXxCANzDk6G9dq6SaEz2g6MT83WIA5qJ9KeTxDmh561wqQqAk2jGU=).\n\nContacts for further information\n\n Media: \n Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com \n Investors: \n Michael Novod +45 3075 6050 nvno@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com \n Alex Bruce +45 3444 2613 axeu@novonordisk.com Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com \n Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com \n Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com \n\nCompany announcement No 50 / 2026\n\nAttachments\n* CA260810_Safe Harbour\n(https://ml-eu.globenewswire.com/Resource/Download/b8280260-28bb-455d-93ee-ec4c58ba82b1)\n \n* 260810_Safe harbour transaction details\n(https://ml-eu.globenewswire.com/Resource/Download/0fc3d292-a907-42d5-b4bb-cab53619c384)"},"type":"article","timestamp":"2026-08-10T13:35:33.169398828Z","server_sent_at_ms":1786368933169},"received_at":"2026-08-10T13:35:33.221Z","source_url":null},"analysis":{"id":"103206","press_release_id":"114207","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"buyback","narrative":"Novo Nordisk repurchased a total of 820,000 B shares between August 4 and August 7, 2026, as part of its ongoing share buyback program.\n\nThe accumulated repurchases under the current tranche initiated in May now total 13.1 million shares, representing an investment of approximately DKK 3.98 billion.\n\nSince the 12-month program began in February, the company has acquired 27.9 million shares for roughly DKK 7.78 billion, utilizing its DKK 15 billion authorization.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine buyback execution data."},"keyFigures":{"customDimensions":{"program_amount_dkk":"15 billion","avg_share_price_dkk":279.01,"accumulated_shares_program":13125000,"accumulated_value_program_dkk":3980067920,"total_shares_repurchased_feb_aug":27884179,"total_value_repurchased_feb_aug_dkk":7780067909}},"quotedText":"","namedEntities":{"people":[{"name":"Ambre James-Brown","role":"Media Contact"},{"name":"Liz Skrbkova","role":"US Media Relations"},{"name":"Michael Novod","role":"Investor Contact"},{"name":"Sina Meyer","role":"Investor Contact"},{"name":"Alex Bruce","role":"Investor Contact"},{"name":"Ida Schaap Melvold","role":"Investor Contact"},{"name":"Christoffer Togo Solgaard-Tullin","role":"Investor Contact"},{"name":"Mads Berner Bruun","role":"Investor Contact"},{"name":"Frederik Taylor Pitter","role":"US Investor Contact"}],"products":[],"companies":[{"name":"Novo Nordisk A/S","ticker":"NOVOB"},{"name":"Nasdaq Copenhagen","relationship":"exchange"},{"name":"New York Stock Exchange","relationship":"exchange"}],"dollarAmounts":[{"amount":"DKK 15 billion","context":"overall share repurchase programme limit"},{"amount":"DKK 11,200,000,010.45","context":"sub-programme limit (May 2026 - Feb 2027)"},{"amount":"DKK 3,980,067,920","context":"accumulated transaction value under current programme"},{"amount":"DKK 7,780,067,909","context":"total transaction value since Feb 4, 2026"}]},"materialImpact":{"score":2,"reasoning":"Routine disclosure of daily share repurchases under an existing program authorized earlier in 2026. No new authorization or strategic shift was announced."},"tickerRelevance":{"others":[{"ticker":"NVO","relevance":"ADR"}],"primary":"NOVOB"},"globalImportance":30,"audienceRelevance":55,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap","eventGravity":"routine_disclosure","sectorWeight":"high"}},"event_type":"buyback","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Novo Nordisk repurchased a total of 820,000 B shares between August 4 and August 7, 2026, as part of its ongoing share buyback program.\n\nThe accumulated repurchases under the current tranche initiated in May now total 13.1 million shares, representing an investment of approximately DKK 3.98 billion.\n\nSince the 12-month program began in February, the company has acquired 27.9 million shares for roughly DKK 7.78 billion, utilizing its DKK 15 billion authorization.","key_figures":{"customDimensions":{"program_amount_dkk":"15 billion","avg_share_price_dkk":279.01,"accumulated_shares_program":13125000,"accumulated_value_program_dkk":3980067920,"total_shares_repurchased_feb_aug":27884179,"total_value_repurchased_feb_aug_dkk":7780067909}},"named_entities":{"people":[{"name":"Ambre James-Brown","role":"Media Contact"},{"name":"Liz Skrbkova","role":"US Media Relations"},{"name":"Michael Novod","role":"Investor Contact"},{"name":"Sina Meyer","role":"Investor Contact"},{"name":"Alex Bruce","role":"Investor Contact"},{"name":"Ida Schaap Melvold","role":"Investor Contact"},{"name":"Christoffer Togo Solgaard-Tullin","role":"Investor Contact"},{"name":"Mads Berner Bruun","role":"Investor Contact"},{"name":"Frederik Taylor Pitter","role":"US Investor Contact"}],"products":[],"companies":[{"name":"Novo Nordisk A/S","ticker":"NOVOB"},{"name":"Nasdaq Copenhagen","relationship":"exchange"},{"name":"New York Stock Exchange","relationship":"exchange"}],"dollarAmounts":[{"amount":"DKK 15 billion","context":"overall share repurchase programme limit"},{"amount":"DKK 11,200,000,010.45","context":"sub-programme limit (May 2026 - Feb 2027)"},{"amount":"DKK 3,980,067,920","context":"accumulated transaction value under current programme"},{"amount":"DKK 7,780,067,909","context":"total transaction value since Feb 4, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-10T19:03:29.886Z","global_importance":30,"audience_relevance":55,"importance_components":{"tickerTier":"mega-cap","eventGravity":"routine_disclosure","sectorWeight":"high"}},"durationMs":145904,"modelName":"glm-4.7"}}